Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Telotristat ethyl (TE) is a treatment for carcinoid syndrome (CS) diarrhea used in combination with somatostatin analog (SSA) therapy. In the Phase 3, randomized, placebo-controlled, double-blind TELESTAR and TELECAST studies, CS patients received TE at 250 mg 3 times per day (tid), 500 mg tid, or placebo tid in addition to SSAs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Dillon J, Kulke M, Warner R, Bergsland E, Welin S,
Keywords: telotristat ethyl, somatostatin analogs, carcinoid syndrome,
Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p<0.0001) between the treatment arms.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Jonathan S
Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,
Keywords: 177Lu-DOTATATE, PRRT, NET, Quality of Life,
#1941 Integrated Safety Analysis of Telotristat Ethyl in Patients with Carcinoid Heart Disease
Introduction: Release of serotonin by neuroendocrine tumors is associated with carcinoid heart disease (CaHD), which may pose challenges for carcinoid syndrome (CS) treatment.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Lapuerta P
Authors: Lapuerta P, Kulke M, Pavel M, Biran T, Fleming R,
Introduction: The tryptophan hydroxylase inhibitor telotristat ethyl (TE) significantly reduced bowel movement (BM) frequency versus placebo (pbo) in patients (pts) with carcinoid syndrome (CS) in the TELESTAR study.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Anthony L, Kulke M, Hörsch D, Bergsland E, Öberg K,